← All trials
NCT04848688
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2021
- Primary completion
- Apr 1, 2022
- Completion date
- Aug 1, 2022
- First posted
- Apr 19, 2021
- Last posted
- Jul 7, 2021
- Enrollment
- 350
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of BaselLead sponsor
- University of BaselSponsor investigator
- University of BaselOverall official - principal investigator
- National Centre for Parasitology, Entomology and Malaria Control, CambodiaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.